Asia-Pacific Ophthalmology Market, By Product (Device, Drugs, and Others), Diseases (Glaucoma, Cataract, Age-Related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Others), Prescription Mode (Generic, and Branded), Drug Type (Prescription, and Over the Counter), Route of Administration (Oral, Topical, Injectables, Local Ocular, and Others), End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
Asia-Pacific Ophthalmology Market Analysis and Size
One of the primary factors driving the growth of the ophthalmology market is the rising prevalence of ophthalmic disorders & ocular pains. The continuing clinical trial research being conducted by several pharmaceutical businesses to better treatment choices and exposure to certain toxins or environmental changes increase the occurrence of ophthalmology products and leads to market expansion. The market is also influenced by increased unhygienic & sedentary lifestyles and a rise in traumatic injuries. However, high cost & risks associated with eye surgery & treatment, lack of health insurance amongst the population, especially within developing countries, and prolonged-time period for manufacturing & formulating ophthalmic drugs acts as restraining factor for the Asia-Pacific ophthalmology market in the forecast period.
Asia-Pacific ophthalmology market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.4% in the forecast period of 2023 to 2030 and is expected to reach USD 18,071.10 million by 2030, from USD 10,224.97 million in 2022.
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customisable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Million
|
Segments Covered
|
By Product Type (Device, Drugs, and Others), Diseases (Glaucoma, Cataract, Age-Related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Others), Prescription Mode (Generic and Branded), Drug Type (Prescription, and Over the Counter (OTC)), Route of Administration (Oral, Topical, Injectables, Local Ocular, and Others), End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
Countries Covered
|
China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and the Rest of Asia-Pacific
|
Market Players Covered
|
Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Reichert, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., Pfizer Inc., and Ziemer Ophthalmic Systems AG
|
Market Definition
Ophthalmology is a branch of medicine that deals with the anatomy, physiology, treatment and surgery of the visual pathways of the eye, including surrounding areas and the visual aspects of the brain. Ophthalmic devices are medical equipment designed for surgery, diagnosis, and vision correction. The devices gained increased importance and adoption due to the high prevalence of several ophthalmic diseases, such as glaucoma, cataract, and other vision-related issues. Ophthalmic drugs are medications that are specially designed and administered for the treatment of various eye-related disorders, including color blindness, diabetic macular edema, cytomegalovirus (CMV), and age-related macular degeneration (AMD).
Ophthalmology Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising prevalence of ophthalmic disorders & ocular pains
Ophthalmic disorders are the vital cause of major ocular and orbital pains in the eye. Ocular pain occurs over the surface of the eyes along with symptoms such as scratching, burning, or itching sensation. This may be due to multiple reasons, including irritation from foreign objects, infection or trauma. Eyelashes or pieces of dirt, smoke, dust or some harsh eye cosmetics are the common causes leading to ocular pain, redness, and watery eyes.
The prevalence of ocular pain keeps showing a surge in growth as chemical industries and pollution around the world are growing. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Style and blepharitis lead to severe ocular pain as they cause eye and oil glands to be more sensitive around the area. The affirmative factor states that this is the major driver for the Asia-Pacific ophthalmology market.
- Rise in traumatic injuries
Traumatic head injury is one of the causes of such disorders as optic nerve disorders. A traumatic injury is a physical injury that occurs suddenly with a certain degree of severity. Trauma can be caused by a variety of external injuries. The most common causes of traumatic injury include road accidents, sports injuries, and violence, among others which can lead to some serious eye disorders as well. The prevalence of such traumatic injuries is highly seen worldwide.
Hence, such traumatic injuries lead to optic nerve disorders, which are affecting the population in these years and it is increasing with the rising population. Therefore, a rise in traumatic injuries is expected to drive market growth.
Opportunities
-
Rise in healthcare expenditure and disposable income
Healthcare expenditure and its growth rate over time are inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system.
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by virtue of accelerating healthcare expenditure.
Growing healthcare expenditure is also beneficial for further economic growth and healthcare sector growth. It is primarily fruitful as it significantly affects the development of better and more advanced medical products in the market. Therefore, the surge in healthcare expenditure may act as a great opportunity for market growth.
-
Rising awareness to prevent the burden of eye diseases
Significant advancements in the prevention of visual impairment have been made to battle visible diseases by various organizations such as World Health Organization (WHO) and its Member States, UN agencies, Non-Governmental Organizations (NGOs) and the private sector. Therefore, the second Thursday of October is World Sight Day (WSD), an annual awareness day to create Asia-Pacific attention on blindness and vision impairment.
Thus, the programs and initiatives to reduce the burden of eye diseases are expected to create opportunities for the growth of the Asia-Pacific ophthalmology market in the forecast period.
Restraints/Challenges
- High cost & risks associated with eye surgery & treatment
The cost of the various disorders treatment plays a major role in the market. The optic nerve disorders treatments are highly sophisticated, as the prevalence of such disorders is increasing; hence the need for such products has eventually raised, thereby raising the treatment cost, which can hinder the market growth in the coming years.
There are various methods for the treatment of optic neuritis disorder. Some of them are patients can take various medicines such as corticosteroids like methylprednisolone, prednisone, immunoglobulin, vitamin B12 shots and various other surgeries. With these, there are some of the risks associated with it.
Therefore, for some of the population around the country, it is difficult for them to undergo such treatments due to the high cost. Hence, the high cost associated with ophthalmic disorders treatment is expected to restrain market growth.
- Lack of skilled professionals
The number of ophthalmologists in both emerging and industrialized countries is minor. However, projections are a little higher for developing countries. The number of ophthalmologists is cumulative but not as fast as the population of elderly patients aged 60 years or older who need to be amplified ophthalmologic care. In most countries, the problem is that demographic changes do not match up with professional development. It is required to train eye care teams to meet the current number of ophthalmologists worldwide. The increased need for ophthalmologists globally also reflects an increase in the cases of diabetes. Diabetic patients should get their eyes inspected every year. The increasing demand for ophthalmologists is directly proportional to the growing geriatric population since eye care is an integral part of healthcare. The access to care gaps can be met by combining factors, including more efficient practice structures, processes and appropriate use of technology.
Post-COVID-19 Impact on the Ophthalmology market
The COVID-19 pandemic had a great impact on the ophthalmology and surgical industries. Trade groups in the ophthalmic and vision products sector claim that the Asia-Pacific supply chain for operating, diagnostic and vision care products has been significantly damaged, impacting end-user consumption of the ophthalmology market. Sales of vision care products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get operated after the lockdown scenario. The situation needs to be taken into consideration, and emergency operations need to be operated. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and vision care instruments.
Recent Developments
- In October 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. This development helps the organization in developing its brand image in the ophthalmology market, among others
- In May 2022, Reichert, Inc. has launched its redesigned refractometers & analytical instruments website with a vastly improved user experience
Asia-Pacific Ophthalmology Market Scope
The Asia-Pacific ophthalmology market is segmented into products, disease, prescription mode, drug type, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Products
- Device
- Drugs
- Others
On the basis of products, the ophthalmology market is segmented into devices, drugs, and others.
Diseases
- Glaucoma
- Cataract
- Age-Related Macular Degeneration
- Inflammatory Diseases
- Refractive Disorders
- Others
On the basis of diseases, the ophthalmology market is segmented into glaucoma, cataracts, age-related macular degeneration, inflammatory diseases, refractive disorders, and others.
Prescription Mode
- Generic
- Branded
On the basis of prescription mode, the ophthalmology market is segmented into generic and branded.
Drug Type
- Prescription
- Over the Counter (OTC)
On the basis of drug type, the ophthalmology market is segmented into prescription and over-the-counter (OTC).
Route of Administration
- Oral
- Topical
- Injectables
- Local Ocular
- Others
On the basis of route of administration, the ophthalmology market is segmented into oral, topical, injectables, local ocular and others.
End User
- Hospitals
- Clinics
- Home Healthcare
- Others
On the basis of end user, the ophthalmology market is segmented into hospitals, clinics, home healthcare, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channels, the ophthalmology market is segmented into direct tender, retail sales, and others.
Ophthalmology Market Regional Analysis/Insights
The Asia-Pacific gaskets market is segmented on the basis of products, disease, prescription mode, drug type, route of administration, end user, and distribution channel.
The regions in the Asia-Pacific gaskets market are China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
China is expected to dominate the Asia-Pacific ophthalmology market due to increasing awareness among consumers about the benefits of ophthalmic surgeries and vision.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data point downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Ophthalmology Market Share Analysis
The ophthalmology market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the Asia-Pacific Ophthalmology market.
Some of the major players operating in this market are Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Reichert, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., Pfizer Inc., and Ziemer Ophthalmic Systems AG, among others.
SKU-